End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,475 IDR | +1.03% | -0.34% | -8.39% |
Feb. 20 | Nomura Adjusts Kalbe Farma’s Price Target to IDR1,850 From IDR2,500, Keeps at Buy | MT |
Oct. 31 | PT Kalbe Farma Tbk. Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.39% | 4.25B | B+ | ||
+33.46% | 701B | C+ | ||
+26.24% | 571B | B | ||
+0.93% | 381B | C+ | ||
+21.03% | 334B | B- | ||
+17.51% | 319B | C+ | ||
+0.74% | 210B | B+ | ||
+2.95% | 210B | B- | ||
-6.05% | 201B | A+ | ||
-3.61% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock PT Kalbe Farma Tbk. - INDONESIA S.E.
- Ratings PT Kalbe Farma Tbk.